A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

Inclusion Criteria: Patients may be included in the study only if they meet all of the following criteria: * Age \> or = 21 years. * Histological or cytological diagnosis of malignant advanced solid tumors refractory to standard therapy or for which no suitable effective standard therapy exists. o Patients who fit above criteria will be pre-screened for presence of 1q21.3 amplification using a plasma assay based on digital PCR. Patients with tumors that exhibit 1q21.3amplification will be enrolled. Positive 1q21.3 amplification is defined as more than 3 standard deviations above the mean comparing the averaged copy number ratio of 3 genes (TUFT1, S100A8 and S100A7) relative to the reference gene RPP30 measure in sample (13). * ECOG 0-2 * Has measureable or evaluable disease based on RECIST 1.1 criteria * Estimated life expectancy of at least 12 weeks. * Has documented progressive disease from last line of therapy * Has recovered from acute toxicities from prior anti-cancer therapies * Adequate organ function including the following: * Bone marrow: * Absolute neutrophil (segmented and bands) count (ANC) \> or = 1.5 x 109/L * Platelets \> or = 100 x 109/L * Hemoglobin \> or = 8 x 109/L * Hepatic: * Bilirubin \< or = 1.5 x upper limit of normal (ULN), * ALT or AST \< or = 2.5x ULN, (or \< or = 5 X with liver metastases) * Renal: * Creatinine \< or = 1.5x ULN * Signed informed consent from patient * Able to comply with study-related procedur…